Introduction/Background/Significance: Across all cancer diagnoses, leptomeningeal involvement is seen in roughly 5% of patients and carries a poor prognosis with median survival under 3 m...
10/17/2025
Introduction/Background/Significance: T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder characterized by the clonal expansion of cytotoxic T-cells...
10/17/2025
Introduction/Background/Significance: Multiple myeloma with CNS involvement is a rare but aggressive manifestation of the disease and is highly associated with poor outcome. Disease contr...
10/17/2025
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the mos
10/27/2026
Introduction/Background/Significance: The phase 3 CEPHEUS study (NCT03652064) established that D-VRd improved overall minimal residual disease (MRD)-negativity rates and progression-free ...
10/27/2026
Introduction/Background/Significance: Mantle cell lymphoma (MCL) predominantly a
10/27/2026
Introduction/Background/Significance: Large language models (LLMs) are increasingly used for medical information retrieval, clinical reasoning, and decision support.
10/27/2026
Introduction/Background/Significance: Transformed Diffuse large B-cell lymphoma (DLBCL) presenting with severe hypercalcemia and rapidly progressive bulky cervical lymphadenopat...
10/27/2026
Introduction/Background/Significance: lugar infrecuente de la aparicionMaterials and Methods/Case Presentation/Objective: se realizo medula osea y pet scan para diagnosticoResults/Descrip...
10/27/2026
Introduction/Background/Significance:
10/27/2026
Introduction/Background/Significance:
10/27/2026
Introduction/Background/Significance: Acute myeloid leukemia (AML) is a common hematologic malignancy found in adults characterized by a range of genetic abnormalities. Next-generation se...
10/17/2025
Introduction/Background/Significance: While the prognosis of Acute Myeloid Leukemia (AML) has improved with the advent of novel therapies, sepsis remains a leading cause of morbidity and ...
10/17/2025
Introduction/Background/Significance: Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) presents a major clinical challenge, particularly in pediatric and young adult...
10/17/2025
Introduction/Background/Significance: Acute myeloid leukemia (AML) is a malignancy associated with altered myeloid lineage precursor hyperplasia and accompanied by different genetic mutat...
10/17/2025
Introduction/Background/Significance: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer in the world. Doxorubicin (Dox) is a very useful drug in these patients, howev...
10/17/2025
Introduction/Background/Significance: Gender disparities in professional visibility remain a significant barrier to achieving equity in oncology and hematology education. Women represent ...
10/17/2025
Introduction/Background/Significance: Social media is a powerful tool for disseminating cancer prevention and early detection information but faces challenges such as gender disparities, ...
10/17/2025
Introduction/Background/Significance: Social media has emerged as a power outlet for medical information, especially in resource-limited regions. However, one third of social media posts ...
10/17/2025
Introduction/Background/Significance: Mutation of DDX41 (Dead/H-box helicase) gene, located on Chromosome 5q35.3, is seen in 1-2% of MDS/AML cases and demonstrates higher overall survival...
10/17/2025
Introduction/Background/Significance: Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder characterized by the Philadelphia chromosome translocation (BCR-ABL1), leadi...
10/17/2025
Introduction/Background/Significance: Isolated neutropenia is often dismissed as benign, particularly in elderly patients where it is typically attributed to age-related marrow changes, m...
10/17/2025
Introduction/Background/Significance: American cancer society is estimating 22, 000 new diagnosis of Acute Myeloid Leukemia (AML) and half of that diagnosis will die from AML. AML account...
10/17/2025
Introduction/Background/Significance: Acute myeloid leukemia accounts for nearly one-third of all leukemia cases and causes over 11,000 deaths annually. Gaps remain in understanding how h...
10/17/2025
Introduction/Background/Significance: According to the American Cancer Society, nearly new cases of chronic myeloid leukemia (CML) are expected to be diagnosed in the United States in 202...
10/17/2025
Introduction/Background/Significance: Immune Thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by platelet count < 100 K/uL. Pathogenesis involves peripheral dest...
10/17/2025
Introduction/Background/Significance: L-asparaginase (L-Asp) remains an essential component in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, its use is often lim...
10/17/2025
Introduction/Background/Significance: A subset of patients (7%-14%) with acute myeloid leukemia (AML) have mutations in the isocitrate dehydrogenase 1 gene (mIDH1). Olutasidenib, a select...
10/17/2025
Introduction/Background/Significance: Chronic myeloid leukemia is characterized by the presence of the BCR-ABL1 oncoprotein, against which the tyrosine kinase inhibitor imatinib was devel...
10/17/2025
Introduction/Background/Significance: Background: Hypereosinophilic syndrome (HES) is defined by persistent eosinophilia ≥1.5×10^9/L, whether associated with eosinophil-mediated organ dam...
10/17/2025
Introduction/Background/Significance: Isocitrate dehydrogenase (IDH) mutations are considered as key metabolic enzymes that lead to the production of the oncometabolite 2-hydroxyglutarate...
10/17/2025
Introduction/Background/Significance: Myelodysplastic syndrome (MDS) is characterized by abnormal blood cell production in the bone marrow. Although exact numbers may vary, approximately ...
10/17/2025
Introduction/Background/Significance: All trans retinoic acid, RA (tretinoin) is structurally related to vitamin A, is effectively used to treat hematological malignancies including acute...
10/17/2025
Introduction/Background/Significance: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis (platelet count ≥450 × 109/L), excl...
10/17/2025
Introduction/Background/Significance: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with thrombotic complications and progressive end-organ dysfunction. Pulmo...
10/17/2025
Introduction/Background/Significance: Elderly patients often present with vague neuropsychiatric symptoms, posing diagnostic challenges. Myeloid sarcoma (MS) is an uncommon manifestation ...
10/17/2025
Introduction/Background/Significance: Palliative care (PC) improves quality of life and end-of-life outcomes for patients with high-risk myelodysplastic syndromes (MDS), yet utilization p...
10/17/2025
Introduction/Background/Significance: Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders categorized into BCR::ABL1-positive chronic myeloid leukemia (CML) and BCR::ABL1...
10/17/2025
Introduction/Background/Significance: Older adults with acute myeloid leukemia (AML) historically experience poor outcomes, particularly those aged ≥75. The introduction of venetoclax-bas...
10/17/2025
Introduction/Background/Significance: Massive splenomegaly is a hallmark manifestation of advanced myeloproliferative neoplasms (MPNs), particularly primary myelofibrosis (PMF) and chroni...
10/17/2025
Introduction/Background/Significance: Background: T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive mature T-cell leukemia, making up 2% of mature leukemias and characterize...
10/17/2025
Introduction/Background/Significance: The skeletal manifestations of Acute Lymphoblastic Leukemia (ALL) usually present as generalized or local bone pain, or joint pain. There are anecdot...
10/17/2025
Introduction/Background/Significance: Over a decade, there was a significant change in the management of patients with Chroni Lymphocytic Leukemia (CLL) from the diagnostic and therapeuti...
10/17/2025
Introduction/Background/Significance: Pregnancy induces a unique immunological state characterized by increased tolerance and controlled immune response.Acute Leukemias as usually seen in...
10/17/2025
Introduction/Background/Significance: Chronic Lymphocytic Leukemia (CLL), a common adult leukemia in Western population remains exceptionally rare among Asians, particularly Filipinos. Mo...
10/17/2025
Introduction/Background/Significance: Guillain-Barré syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy usually triggered by infections. Arsenic Trioxide (ATO) and All T...
10/17/2025
Introduction/Background/Significance: The advent of Bruton tyrosine kinase inhibitors has significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL). However, as...
10/17/2025
Introduction/Background/Significance: The emergence of targeted agents, including BCL2 inhibitor venetoclax and Bruton's tyrosine kinase inhibitors (BTKis), has transformed the management...
10/17/2025
Introduction/Background/Significance: Obesity and metabolic dysfunction are common in patients with hematological malignancies (such as lymphoma, leukemia, myeloma, myelodysplastic syndro...
10/17/2025
Introduction/Background/Significance: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR-ABL1 fusion gene with overproduction of granulocytes and typically ...
10/17/2025
Introduction/Background/Significance: Background: Treating aggressive relapsed or refractory (R/R) non-hodgkin lymphoma (NHL) can be challenging, especially for those patients progressing...
10/17/2025
Introduction/Background/Significance: CLL is one of the most common types of leukemia. With new advances, we’ve seen an increase in survival for patients, yet there's still a lot we can l...
10/17/2025
Introduction/Background/Significance: CD19-directed CAR-T cell therapy has transformed the treatment landscape for relapsed/refractory B-cell lymphomas. Nevertheless, the risk of immune e...
10/17/2025
Introduction/Background/Significance: Chronic lymphocytic leukemia (CLL) is a disease primarily of the elderly, however, in rare cases, it can occur among adolescent and young adults (AYA...
10/17/2025
Introduction/Background/Significance: Cardiac involvement by extranodal NK/T-cell lymphoma (ENKTL) is exceedingly rare and almost uniformly fatal, largely because diagnosis is delayed and...
10/17/2025
Introduction/Background/Significance: Hyperleukocytosis (WBC >100,000/μL), typically seen in acute leukemia, can also occur in chronic myeloid leukemia (CML) and is associated with hig...
10/17/2025
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin lymphoma. A subset known as double-expressor lymphoma (DEL), ...
10/17/2025
Introduction/Background/Significance Chronic lymphocytic leukemia (CLL) typically follows an indolent course and is often managed expectantly in early stages such as Rai stage 0. Pulmonar...
10/17/2025
Introduction/Background/Significance: Lymphoma-associated paraneoplastic neuropathy is uncommon, accounting only 6.4% of cases. The central and peripheral nervous systems may be affected,...
10/17/2025
Introduction/Background/Significance: Although BTK inhibitors (BTKi) are effective in chronic lymphocytic leukemia (CLL), the emergence of BTKi resistance mutations and identification of ...
10/17/2025
Introduction/Background/Significance: Hodgkin lymphoma, though rare, continues to carry a high mortality rate. Despite favorable five-year survival rates, there remains a knowledge gap re...
10/17/2025
Introduction/Background/Significance: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries, typically affecting older adults and characterized by cl...
10/17/2025
Introduction/Background/Significance: Rasburicase is widely used to prevent tumor lysis syndrome (TLS) in high-risk hematologic malignancies. However, in patients with glucose-6-phosphate...
10/17/2025
Introduction/Background/Significance: Methotrexate (MTX), an immunosuppressant used for rheumatoid arthritis (RA) and inflammatory myopathies, predisposes patients to lymphoproliferative ...
10/17/2025
Results/Description/Main Outcome Measures: Of the 180 DLBCL driver genes analyzed, 16 were found to mutate at a different frequency by age of diagnosis. These included both well-known onc...
10/17/2025
Introduction/Background/Significance: Shortening chemotherapy infusion times is associated with improvements in resource use and patient satisfaction, as well as reductions in nursing wor...
10/17/2025
Introduction/Background/Significance: Large granular lymphocytic (LGL) leukemia is a rare, indolent lymphoproliferative disorder often associated with cytopenias and autoimmune features. ...
10/17/2025
Introduction/Background/Significance: T-prolymphocytic leukemia (T-PLL) is a rare mature T-cell neoplasm, accounting for approximately 2% of adult leukemias. It primarily affects older ad...
10/17/2025
Introduction/Background/Significance: Currently approved bispecific antibodies for R/R DLBCL require inpatient monitoring. Epcoritamab is a CD3×CD20 bispecific antibody approved for R/R D...
10/17/2025
Introduction/Background/Significance: NK/T-cell lymphoma is an aggressive and rare subtype of non-Hodgkin lymphoma
10/17/2025
Introduction/Background/Significance: Loss of CD20 expression in B-cell lymphoma is rare but clinically significant, often leading to disease progression and resistance to anti-CD20 based...
10/17/2025
Introduction/Background/Significance: R-mini-CHOP is commonly used for treatment of elderly, frail patients with newly diagnosed LBCL. However, many patients are not suitable candidates f...
10/17/2025
Introduction/Background/Significance: Delayed presentation in lymphoma patients worsens outcomes, particularly in resource-limited settings like Nigeria. This study examines factors assoc...
10/17/2025
Introduction/Background/Significance: Cognitive impairment related to cancer or chemotherapy (CRCI) is frequently reported in Hodgkin lymphoma (HL) patients, but the influence of treatmen...
10/17/2025
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, typically managed with R-CHOP chemotherapy. While transformation withi...
10/17/2025
Introduction/Background/Significance: Methotrexate (MTX), an immunosuppressant used for rheumatoid arthritis (RA) and inflammatory myopathies, predisposes patients to lymphoproliferative ...
10/17/2025
Introduction/Background/Significance: Lymphoma diagnosis relies on histologic examination, immuno-profiling, and often fluorescence in situ hybridization (FISH). Because FISH is perf...
10/17/2025
Introduction/Background/Significance: The B-cell receptor signaling pathway mediated by BTK is a validated therapeutic target in Waldenström macroglobulinemia (WM). Bexobrutideg is a nov...
10/17/2025
Introduction/Background/Significance: Viruses have long been implicated in human oncogenesis, with Epstein–Barr virus (EBV) serving as a prototype of latent viral persistence capable of d...
10/17/2025
Introduction/Background/Significance: Follicular lymphoma (FL) is classically indolent but may transform into aggressive disease such as high-grade B-cell lymphoma with MYC and BCL2 rearr...
10/17/2025
Introduction/Background/Significance: Elranatamab induced deep and durable responses with manageable safety in BCMA-naive patients with RRMM in MagnetisMM-3 (NCT04649359). Combining elran...
10/17/2025
Introduction/Background/Significance: Splenic marginal zone lymphoma (SMZL) is a rare subtype of non-Hodgkin lymphoma (NHL), representing < 1% of all NHLs. The annual incidence is appr...
10/17/2025
Introduction/Background/Significance: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy that has shown promising efficacy in patients...
10/17/2025
Introduction/Background/Significance: The first-line standard-of-care for diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednison...
10/17/2025
Introduction/Background/Significance: Multiple Myeloma (MM) is a Hematological malignancy of B-cell plasma cell that affects elderly population. It is the second most common malignancy af...
10/17/2025
Introduction/Background/Significance: Patients with relapsed/refractory multiple myeloma (RRMM) often undergo numerous lines of therapy, including novel bispecific agents such as talqueta...
10/17/2025
Introduction/Background/Significance: Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved for R/R FL after ≥2 prior lines of therapy (pLOT; 3L+) based on the phase 1/2 tri...
10/17/2025
Introduction/Background/Significance: CAR T therapy is a treatment option for patients with relapse/refractory multiple myeloma (RRMM), however optimizing treatment outcomes may depend on...
10/17/2025
Introduction/Background/Significance: Asciminib, a BCR-ABL1 tyrosine kinase inhibitor (TKI) that specifically targets the ABL myristoyl pocket, serves as a therapeutic option for patients...
10/17/2025
Introduction/Background/Significance: Monoclonal antibodies targeting CD38 (α-CD38), in combination with agents like bortezomib, carfilzomib, and lenalidomide, are a standard therapy for ...
10/17/2025
Introduction/Background/Significance: The programmed cell death protein 1 (PD-1) inhibitor pembrolizumab is a standard-of-care treatment option for multiple cancers, including relapsed or...
10/17/2025
Introduction/Background/Significance: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at both national and global levels...
10/17/2025
Introduction/Background/Significance: Nemtabrutinib, a potent, noncovalent, reversible Bruton tyrosine kinase inhibitor (BTKi) taken by mouth (PO) once daily (QD), has shown promising ant...
10/17/2025
Introduction/Background/Significance: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at both national and global levels...
10/17/2025
Introduction/Background/Significance: Nemtabrutinib, a potent, noncovalent, reversible Bruton tyrosine kinase inhibitor (BTKi) taken by mouth (PO) once daily (QD), has shown encouraging a...
10/17/2025
Introduction/Background/Significance: Multiple myeloma (MM) is a malignant plasma cell disorder that primarily affects the bone marrow, leading to hematologic complications, bone destruct...
10/17/2025
Introduction/Background/Significance: In LBCL, duration of CR (DOCR) correlates with long-term outcomes. Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, is approved for patients...
10/17/2025
Introduction/Background/Significance: Background: Adolescent and young adult (AYA) patients between the ages of 15 and 39 form a distinct and under-researched group in oncology. Myeloma i...
10/17/2025
Introduction/Background/Significance: Hematopoietic cell transplantation (HCT) is essential for eligible patients with relapsed/refractory classical Hodgkin lymphoma (R/RcHL), but optimal...
10/17/2025
Introduction/Background/Significance: Waldenström Macroglobulinemia (WM) is a rare, indolent B-cell lymphoma characterized by the production of monoclonal IgM antibodies. While typical s...
10/17/2025
Introduction/Background/Significance: Hodgkin's lymphoma (HL) is a hematologic malignancy characterized by the presence of Reed-Sternberg cells and commonly presents with lymphadenopathy,...
10/17/2025
Introduction/Background/Significance: Plasma cell leukemia (PCL) is defined as >2 × 109/liter plasma cells (PCs) in peripheral blood or by >20% in differential leukocyte count. Seco...
10/17/2025
Introduction/Background/Significance: Non-Hodgkin lymphoma (NHL) can be either indolent or aggressive. Breast involvement by NHL, either primary or secondary is rare, with an incidence of...
10/17/2025
Introduction/Background/Significance: Multidisciplinary lifestyle medicine education for patients with multiple myeloma is limited despite lifestyle evidence-based recommendations for can...
10/17/2025
Introduction/Background/Significance: A 42-year-old male presented with malaise, fatigue, generalized lymphadenopathy, and splenomegaly. Lymph node biopsy confirmed a diagnosis of Hodgkin...
10/17/2025
Introduction/Background/Significance: Ciltacabtagene autoleucel (cilta-cel) is a BCMA-directed CAR-T cell therapy approved in the US for relapsed/refractory multiple myeloma (RRMM) as ear...
10/17/2025
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal condition characterized by immune hyperactivation. Malignancies (like lymphomas), autoimmune diseases, ...
10/17/2025
Introduction/Background/Significance: CML is a MPN characterized by the presence of the Philadelphia chromosome t(9;22),. Most patients are diagnosed in chronic phase. Introduction of TKI...
10/21/2025
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma, accounting for 30–40% of cases. It is an aggressive mali...
10/17/2025
Introduction/Background/Significance: Palliative care (PC) improves quality of life and end-of-life outcomes for patients with high-risk myelodysplastic syndromes (MDS), yet utilization p...
02/02/2026
Introduction/Background/Significance: Primary pancreatic follicular lymphoma (PPFL) is an extremely rare subtype of extranodal follicular lymphoma, accounting for 0.1%-0.5% of malignant l...
10/17/2025
Introduction/Background/Significance: Cardiac involvement by extranodal NK/T-cell lymphoma (ENKTL) is exceedingly rare and almost uniformly fatal, largely because diagnosis is delayed and...
02/02/2026
Introduction/Background/Significance: Gray Zone Lymphoma (GZL), "B-cell lymphoma, unclassifiable, with features intermediate between Diffuse large B cell Lymphoma and classical Hodgkin ly...
10/17/2025
Introduction/Background/Significance: Waldenström Macroglobulinemia (WM) is a rare, indolent B-cell lymphoma characterized by the production of monoclonal IgM antibodies. While typical sy...
02/02/2026
Introduction/Background/Significance: The simultaneous diagnosis of two distinct primary malignancies, known as synchronous malignancies, is rare but increasingly recognized, with reporte...
10/17/2025
Introduction/Background/Significance: Primary Bone Lymphoma is a rare disease that accounts to approximately 1% of lymphomas and 3-7% of all primary bone tumors. The presentation is ...
10/27/2026
Introduction/Background/Significance: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized management for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), but rea...
10/17/2025
Introduction/Background/Significance: Plasmablastic Lymphoma (PBL) is an aggressive B- cell lymphoma, usually associated with immunocompromised conditions. Materials and Methods/Case Pres...
10/27/2026
Introduction/Background/Significance: Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin lymphoma with an incidence of approximately 8.5 cases per million individuals. Central nervous...
10/17/2025
Introduction/Background/Significance: Patients with multiple myeloma experience high symptom burden and intensive healthcare utilization near the end of life, yet palliative care remains ...
10/27/2026
Introduction/Background/Significance: Waldenström macroglobulinemia (WM) is a rare, indolent, IgM‑producing lymphoplasmacytic lymphoma that predominantly affects older adults. In this stu...
10/27/2026
Introduction/Background/Significance: Therapeutic PD-1/PDL-1 (Programmed Death Ligand) inhibition is associated with hyper-progression of certain T-cell malignancies. PD-1 receptor is a k...
10/17/2025
Introduction/Background/Significance: Cardiac amyloidosis is a progressive infiltrative cardiomyopathy associated with significant morbidity and mortality. Monoclonal gammopathies may coe...
10/27/2026
Introduction/Background/Significance: Chimeric antigen receptor (CAR) T-cell therapies have transformed the landscape of treatment for relapsed or refractory (R/R) large B-cell lymphoma (...
10/17/2025
Introduction/Background/Significance: Background:MagnetisMM-6 (NCT05623020) is a phase 3, open-label, randomized study evaluating EDR versus daratumumab+bortezomib+lenalidomide+dexamethas...
10/27/2026
Introduction/Background/Significance: Hemophagocytic Lymphohistiocytosis (HLH) can be primary (Genetic) or Secondary (Acquired). Secondary causes of HLH include infections, malignancy, au...
10/17/2025
Introduction/Background/Significance: Dasatinib is a second-generation BCR::ABL1 tyrosine kinase inhibitor widely used for chronic myeloid leukemia (CML). Although pleural effusion and fl...
10/27/2026
Introduction/Background/Significance: Light chain (AL) amyloidosis is a relatively uncommon but clinically significant complication of multiple myeloma with important prognostic and manag...
10/17/2025
Introduction/Background/Significance: Over a decade, significant changes in the management of patients with Chronic Lymphocytic Leukemia (CLL) had occurred with respect to diagnostic and ...
10/27/2026
Introduction/Background/Significance: Elranatamab (ELRA) is a humanized bispecific antibody that targets both B-cell maturation antigen (BCMA)-expressing multiple myeloma (MM) cells and C...
10/17/2025
Introduction/Background/Significance: Multiple Myeloma (MM) is a Hematological malignancy of B-cell plasma cell that affects elderly population. It is the second most common malignancy af...
10/27/2026
Materials and Methods/Case Presentation/Objective: We performed a retrospective cohort analysis using the TriNetX Network. Patients aged ≥70 years with RRMM treated with either CAR-T (n=3...
10/17/2025
Introduction/Background/Significance: Juvenile myelomonocytic leukemia (JMML) is defined by constitutive RAS/MAPK activation, yet convergence on a shared signaling pathway may obscure sub...
10/27/2026
Introduction/Background/Significance: Bortezomib, a proteasome inhibitor, has significantly improved survival outcomes in multiple myeloma (MM). However, resistance remains a major barrie...
10/17/2025
Introduction/Background/Significance: Juvenile myelomonocytic leukemia (JMML) is characterized by aberrant RAS-pathway signaling, yet its biological heterogeneity may extend well beyond t...
10/27/2026
Introduction/Background/Significance: The therapeutic landscape for relapsed/refractory multiple myeloma (RRMM) continues to evolve with the introduction of novel agents such as belantama...
10/17/2025
Introduction/Background/Significance: Rogers syndrome (thiamine-responsive megaloblastic anemia, TRMA) is a rare autosomal recessive disorder caused by biallelic SLC19A2 pathogenic varian...
10/27/2026
Introduction/Background/Significance: Multiple myeloma is a clonal plasma cell proliferative disorder in which excess production of monoclonal immunoglobulins by plasma cells leads to end...
10/17/2025
Introduction/Background/Significance: Hodgkin lymphoma (HL) is a highly curable malignancy, but outcomes in low- and middle-income countries may be affected by delayed diagnosis and limit...
10/27/2026
Introduction/Background/Significance: Primary light chain (AL) amyloidosis and multiple myeloma (MM) are both clonal plasma cell disorders. AL amyloidosis and MM are distinguished primari...
10/17/2025
Introduction/Background/Significance: The synchronous occurrence of acute myeloid leukemia (AML) and T-cell lymphoblastic lymphoma (T-LBL) is exceptionally rare and poses significant diag...
10/27/2026
Introduction/Background/Significance: Multiple myeloma (MM) frequently manifests with severe bone involvement, including vertebral pathological fractures and mechanical instability, leadi...
10/17/2025
Introduction/Background/Significance: Abdominal radiotherapy for B-cell lymphoma (BCL) is constrained by gastrointestinal and hematologic toxicity, owing to off-target effects within the ...
10/27/2026
Introduction/Background/Significance: The ongoing phase 2 MagnetisMM-3 (NCT04649359) study demonstrated the efficacy and safety of ELRA in patients (pts) with RRMM and no prior BCMA-direc...
10/17/2025
Introduction/Background/Significance: Elranatamab (ELRA), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, induced deep and durable responses with a manageable safety profile i...
10/17/2025
Introduction/Background/Significance: IgM multiple myeloma (MM) is a rare plasma cell malignancy representing less than 0.5% of all MM cases. It presents a unique diagnostic challenge due...
10/17/2025
Introduction/Background/Significance: At Mount Sinai Health System (MSHS), hypercalcemia is defined as a corrected serum calcium (CSC) level of at least 10.5 mg/dL or an ionized calcium l...
10/17/2025
Introduction/Background/Significance: D-VRd is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). In CEPHEUS (NCT03652064), D-VRd improved...
10/17/2025
Introduction/Background/Significance: For patients with Non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) who require an autologous stem cell transplant (ASCT), there are several strat...
10/17/2025
Introduction/Background/Significance: Multiple myeloma (MM) remains primarily a disease of the elderly, with a median age of 66 at presentation. Though the development of newer therapeuti...
10/17/2025
Introduction/Background/Significance: Plasma cell tumors include solitary plasmacytomas and multiple myeloma (MM). Extramedullary plasmacytomas (EMP) are rare soft tissue manifestations o...
10/17/2025
Introduction/Background/Significance: Autologous stem cell transplant (ASCT) is essential in Multiple Myeloma to increase progression free survival. After graft infusion, Neutrophil engra...
10/17/2025
Introduction/Background/Significance: Multiple myeloma carries a high disease burden, with only a 62% survival rate at the five-year mark. However, little is known about the factors that ...
10/17/2025
Introduction/Background/Significance: Plasmacytoma is a rare malignancy of monoclonal plasma cells, with tracheal involvement being exceptionally uncommon. Its indolent course can delay d...
10/17/2025
Introduction/Background/Significance: In the phase 3, randomized DREAMM-7 and DREAMM-8 trials, belamaf plus standard backbone therapies demonstrated significant progression-free survival ...
10/17/2025
Introduction/Background/Significance: Multiple Myeloma (MM) is an abnormal growth of plasma cells in the bone marrow and remains a major contributor to mortality. The current treatments f...
10/17/2025
Introduction/Background/Significance: Only 20-50% of eligible patients with multiple myeloma (MM) undergo autologous stem cell transplantation (ASCT). Community oncologists commonly refer...
10/17/2025
Introduction/Background/Significance: Plerixafor is an inhibitor molecule with ability for reversible binding to CXCR-4 receptor – followed by superior stem cell (SC) release/mobilization...
10/17/2025
Introduction/Background/Significance: Type I cryoglobulinemia develops in the setting of monoclonal gammopathies for about 10-15% of cases. Clinically patient's will present with severe c...
10/17/2025
Introduction/Background/Significance: Few studies have assessed the outcomes of CAR T-cell therapy in patients with end-stage renal disease (ESRD). Data remain especially limited in the c...
10/17/2025
Introduction/Background/Significance: Richter transformation (RT) typically involves transformation of chronic lymphocytic leukemia (CLL) into aggressive B-cell lymphoma. The transformati...
10/17/2025
Introduction/Background/Significance: The B-cell receptor signaling pathway mediated by BTK is a validated therapeutic target in Waldenström macroglobulinemia (WM). Bexobrutideg is a nove...
02/02/2026
Introduction/Background/Significance: In LBCL, duration of CR (DOCR) correlates with long-term outcomes. Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, is approved for patients...
02/02/2026
Introduction/Background/Significance: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized management for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), but rea...
02/02/2026
Introduction/Background/Significance: Pregnancy in chronic myeloid leukemia (CML) presents a complex clinical challenge due to the necessary interruption of tyrosine kinase inhibitors (TK...
10/27/2026
Introduction/Background/Significance: Bone marrow necrosis (BMN) is rare and is attributed to marrow microcirculatory failure, usually associated with malignancy. BMN has been reported du...
10/27/2026
Introduction/Background/Significance: Chronic eosinophilic leukemia (CEL) is a rare clonal myeloproliferative neoplasm accounting for less than 1% of all MPNs.
10/27/2026
Introduction/Background/Significance:
10/27/2026
Introduction/Background/Significance: Efficient mobilization of hematopoietic stem cells (HSCs) is essential for successful allogeneic transplantation. CD34+ cell count serves as the prim...
10/27/2026
Introduction/Background/Significance: BackgroundMyeloid sarcoma (MS) is a rare extramedullary tumor composed of immature myeloid cells that may occur concurrently with acute myeloid leuke...
10/27/2026
Introduction/Background/Significance:
10/27/2026
Introduction/Background/Significance: Previous studies address the role of GDF11 in initiation and progression of fibrosis in different pathological conditions.
10/27/2026
Introduction/Background/Significance:
10/27/2026
Introduction/Background/Significance: Capillary leak syndrome (CLS) after autologous hematopoietic cell transplant (HSCT) is a rare, potentially fatal complication overlapping with engraf...
10/27/2026
Introduction/Background/Significance: Outcomes in newly diagnosed multiple myeloma (NDMM) have improved significantly, yet real-world data from Latin America remains limited. We aimed to ...
10/27/2026
Introduction/Background/Significance: Advancements in relapsed/refractory multiple myeloma (RRMM) treatment with BCMA-targeted agents have revolutionized outcomes; however, an unmet need ...
10/27/2026
Introduction/Background/Significance: Lymphomatoid papulosis (LyP) is a rare indolent lymphoproliferative disorder characterized by recurrent papules and nodules due to abnormal CD30+ T-c...
10/27/2026
Introduction/Background/Significance: Extramedullary relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation is an uncommon but clinically challenging ...
10/27/2026
Introduction/Background/Significance: For more than two decades, tyrosine kinase inhibitors (TKIs) represent the revolution of treatment for patients with Philadelphia chromosome-positive...
10/27/2026
Introduction/Background/Significance: Pirtobrutinib (Jaypirca) is the first non-covalent, reversible Bruton
10/27/2026
Introduction/Background/Significance: The 2014 IMWG revised diagnostic criteria expanded multiple myeloma (MM) diagnosis beyond CRAB features to include myeloma-defining biomarkers, enabl...
10/27/2026
Introduction/Background/Significance: Kikuchi-Fujimoto disease (KFD) is a benign ne
10/27/2026
Introduction/Background/Significance: Paraneoplastic antiphospholipid syndrome (APS) is a rare autoimmune complication of multiple myeloma (MM) in which the malignant plasma cell clone ma...
10/27/2026
Introduction/Background/Significance: Bispecific antibodies targeting B-cell maturation antigen (BCMA) and G protein-coupled receptor family C group 5 member D (GPRC5D) have rapidly becom...
10/27/2026
Introduction/Background/Significance: Plasmablastic lymphoma (PBL) is a rare and highly aggressive subtype of diffuse large B-cell lymphoma, strongly associated with HIV infection and cha...
10/27/2026
Introduction/Background/Significance: Time-to-first-treatment (TTFT) is a clinically relevant endpoint in chronic lymphocytic leukemia (CLL), reflecting the interval from diagnosis to ini...
10/27/2026
Introduction/Background/Significance: The estimated incidence of pregnancy-associated cancer is approximately 1 in 1000, of which 25% are diagnosed during pregnancy. In this case report,...
10/27/2026
Introduction/Background/Significance: Covalent Bruton tyrosine kinase inhibitors have significantly improved outcomes in chronic lymphocytic leukemia; however, treatment discontinuation d...
10/27/2026
Introduction/Background/Significance: Although BTK inhibition has transformed CLL/SLL management, the emergence of resistance mutations and kinase-independent scaffolding signaling unders...
10/27/2026
Introduction/Background/Significance: BACKGROUND:
10/27/2026
Introduction/Background/Significance: Extramedullary disease (EMD) is a high-risk manifestation of multiple myeloma (MM), reflecting aggressive plasma cell biology, altered tissue tropism...
10/27/2026
Introduction/Background/Significance: Background:
10/27/2026
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma.
10/27/2026
Introduction/Background/Significance:
10/27/2026
Introduction/Background/Significance: ALK-negative anaplastic large cell lymphoma (ALCL) is an uncommon peripheral T-cell lymphoma that may present with extensive cutaneous involvement. E...
10/27/2026
Introduction/Background/Significance: Peripheral T-cell lymphomas (PTCL) are rare, heterogeneous, aggressive non-Hodgkin lymphomas. Five-year overall survival remains approximately 30-40%...
10/27/2026
Introduction/Background/Significance: The Prognostic Nutritional Index (PNI), calculated from serum albumin and lymphocyte count, reflects nutritional and immunological status. Its indepe...
10/27/2026
Introduction/Background/Significance: Tyrosine kinase inhibitors (TKIs) like imatinib have revolutionized chronic myeloid leukemia (CML) management, converting a fatal malignancy into a m...
10/27/2026
Introduction/Background/Significance: Clival plasmacytomas are an exceptionally rare manifestation of multiple myeloma (MM), with roughly 70 reported cases. One heralding relapse in previ...
10/27/2026
Introduction/Background/Significance: Obesity's relationship with cancer prognosis is often assumed to be uniformly unfavorable, but a well-documented "obesity paradox" exists in several ...
10/27/2026
Introduction/Background/Significance: Frailty has been increasingly recognized as an impo
10/27/2026
Introduction/Background/Significance: Primary cutaneous B-cell lymphomas (PCBCL) account for 25% of all primary cutaneous lymphomas. Primary Cutaneous Marginal Zone Lymphoma (PCMZL) is a ...
10/27/2026
Introduction/Background/Significance: For patients with RRMM, outcomes worsen with each successive line of therapy (LOT). Talquetamab, a first-in-class GPRC5D×CD3 bispecific antibody, dem...
10/27/2026
Introduction/Background/Significance: Multiple myeloma (MM) remains largely incurable despite novel agents.
10/27/2026
Introduction/Background/Significance: Mantle cell lymphoma (MCL) predominantly affects older adults and often presents with advanced-stage disease, posing significant therapeutic challeng...
10/27/2026
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) rarely involves the heart, and cardiac tamponade as the initial presentation is exceedingly uncommon....
10/27/2026
Introduction/Background/Significance: Bispecific antibodies (BsAbs) have transformed the treatment of relapsed/refractory multiple myeloma (RRMM), although pivotal trials may underreprese...
10/27/2026
Introduction/Background/Significance: T-cell-engaging bispecific antibodies (BsAb) have become integral therapies for relapsed or refractory hematologic malignancies but are frequently co...
10/27/2026
Introduction/Background/Significance:
10/27/2026
Introduction/Background/Significance: Renal impairment is a common and serious complication of multiple myeloma (MM), affecting 20-50% of patients at diagnosis, with light-chain cast neph...
10/27/2026
Introduction/Background/Significance: BCMA-directed bispecific antibodies have transformed the treatment of RRMM, but induce prolonged humoral and cellular immune dysfunction, predis...
10/27/2026
Introduction/Background/Significance: Wunderlich syndrome (WS) is a rare, spontaneous, non-traumatic renal or perirenal hemorrhage that may result in life-threatening hemodynamic instabil...
10/27/2026
Introduction/Background/Significance: Autoimmune hemolytic anemia (AIHA) is a recognized paraneoplastic complication of lymphoid malignancies, most frequently seen with chronic lymphocyti...
10/27/2026
Introduction/Background/Significance: Elderly patients with diffuse large B-cell lymphoma (DLBCL) who are ineligible for R-CHOP have limited first-line options. R-miniCHOP achieves comple...
10/27/2026
Introduction/Background/Significance: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare and aggressive variant of diffuse large B-cell lymphoma, accounting for approximatel...
10/27/2026
Introduction/Background/Significance: Bruton's tyrosine kinase (BTK) plays a central role in the B-cell receptor (BCR) signaling pathway and is involved in the pathogenesis of several B-c...
10/27/2026
Introduction/Background/Significance: Efficacious new treatments are needed for RRMM patients (pts) with prior anti-CD38 antibody (Ab) and lenalidomide (len) exposure. FcRH5 is ubiquitous...
10/27/2026
Introduction/Background/Significance: Plasmablastic lymphoma(PBL) is an aggressive form of B-cell lymphoma.
10/27/2026
Introduction/Background/Significance: Myeloid sarcoma (MS) is a rare extramedullary tumor composed of immature myeloid blasts that may occur in association with acute myeloid leukemia or ...
10/27/2026
Introduction/Background/Significance: INTRODUCTION: HIV-associated lymphomas are characterized by marked biological heterogeneity and often aggressive behavior, yet sequential evolution a...
10/27/2026
Introduction/Background/Significance: 1.
10/27/2026
Introduction/Background/Significance: Fever of unknown origin remains a diagnostic challenge, but fever patterns may provide important clues. Pel-Ebstein fever is a rare cyclica...
10/27/2026
Introduction/Background/Significance: Classical Hodgkin lymphoma (CHL) generates sarcoid-like granulomatous reactions in approximately 13.8% of cases, occasionally obscuring sparse Hodgki...
10/27/2026
Introduction/Background/Significance: Immune checkpoint inhibitors have significantly improved outcomes in relapsed/refractory classical Hodgkin lymphoma (cHL), but atypical response patt...
10/27/2026
Introduction/Background/Significance: To evaluate the real-world efficacy and safety of Polatuzumab Vedotin-based regimens in treatment-naive patients with diffuse large B-cell lymphoma (...
10/27/2026
Introduction/Background/Significance: 1. Introduction:
10/27/2026
Introduction/Background/Significance: Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive lymphoma of adolescents and young adults that often presents as a bulky anterior mediast...
10/27/2026
Introduction/Background/Significance: Primary gastrointestinal follicular lymphoma (PGI-FL) is a rare subset of extranodal non-Hodgkin lymphoma, traditionally characterized by localized, ...
10/27/2026
Introduction/Background/Significance: Multiple myeloma remains a major hematologic malignancy associated with substantial mortality despite advances in diagnosis and treatment. We evaluat...
10/27/2026
Introduction/Background/Significance: Bispecific antibodies (BsAb) are increasingly used in multiple myeloma (MM), but patient understanding of their mechanism, toxicity, logistics ...
10/27/2026
Introduction/Background/Significance: Classical Hodgkin lymphoma (cHL) and folicular lymphoma (FL) are biologically distinct B-cell lymphomas that rarely occur synchronously. Their c...
10/27/2026
Introduction/Background/Significance: Necrobiotic xanthogranuloma is a rare non-Langerhans cell histiocytosis (CD68-positive, CD1a-negative) characterized by yellow to red-brown papules, ...
10/27/2026
Introduction/Background/Significance: Castleman disease is a lymphoproliferative disorder marked by benign overgrowth of lymphoid tissue, split into unicentric (UCD) and multicentric (MCD...
10/27/2026
Introduction/Background/Significance: Non-Hodgkin lymphomas (NHL) are heterogeneous lymphoid malignancies with diverse clinical and histopathological features.
10/27/2026
Introduction/Background/Significance: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is a standard consolidation strategy for patients with r...
10/27/2026
Introduction/Background/Significance: Renal impairment is highly prevalent in multiple myeloma and remains a major determinant of treatment eligibility, tolerability, and long-term outcom...
10/27/2026
Introduction/Background/Significance: Talquetamab, a first-in-class bispecific T-cell engager (BiTE) targeting G protein-coupled receptor class C group 5 member D (GPRC5D), has emerged as...
10/27/2026
Introduction/Background/Significance: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome characterized by severe hypercytokinemia and multi-or...
10/27/2026
Introduction/Background/Significance: Epstein-Barr virus (EBV) is a well-established trigger of hemophagocytic lymphohistiocytosis (HLH), an intense hyperinflammatory syndrome driven by c...
10/27/2026
Introduction/Background/Significance: Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma universally associated with Epstein-Barr virus (EBV). ENKTL t...
10/27/2026
Introduction/Background/Significance: Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare extranodal lymphoma accounting for 1-2% of all non-Hodgkin lymphomas (NHL) and ...
10/27/2026
Introduction/Background/Significance: Teclistamab, a B-cell maturation antigen (BCMA)-directed bispecific antibody, has expanded treatment options for relapsed or refractory multiple myel...
10/27/2026
Introduction/Background/Significance: Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV-positive DLBCL), is an aggressive lymphoid malignancy that ma...
10/27/2026
Introduction/Background/Significance: Chronic kidney disease (CKD) is a major complication of multiple myeloma (MM) and contributes substantially to morbidity and mortality. Contemporary ...
10/27/2026
Introduction/Background/Significance: JAGN1-associated neutropenia is a rare autosomal recessive form of severe congenital neutropenia (SCN), with fewer than 35 patients reported worldwid...
10/27/2026
Introduction/Background/Significance: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients aged ≥65 who are ineligible for or declining chimeric antigen receptor T...
10/27/2026
